Launched in March 2017, BigData@Heart is a five-year project of the Innovative Medicines Initiative (IMI), a public-private initiative between the European Union and the pharmaceutical industry association EFPIA.

BigData@Heart aims to develop a data-driven translational research platform towards improving patient outcomes and therefore reducing the societal burden of Atrial Fibrillation (AF), Acute Coronary Syndrome (ACS) and Heart Failure (HF) in Europe.

The BigData@Heart consortium brings together 19 partners ranging from leading epidemiologists and big data scientists, to patient and cardiovascular professional organisations, as well as pharmaceutical industry representatives.  The European Heart Network will be representing the views of those living with these cardiovascular diseases as well as ensuring that key findings are disseminated among patient organisations and policy makers, with a view to improving current clinical practice and policies.

BigData@Heart is one of the four disease-specific consortia of the IMI Programme Big Data for Better Health Outcomes.

The BigData@Heart consortium partners are (in alphabetical order):
BAYER, Charité - Universitätsmedizin Berlin, European Heart Network, European Society of Cardiology, Fundación para la investigación del Hospital Clinico de la Comunidad Valenciana, International Consortium for Health Outcomes Measurement, Karolinska Institutet, MLC Foundation, NOVARTIS, SERVIER, SomaLogic, The Hyve, Universitätsklinikum Hamburg-Eppendorf, University College London, University Medical Center Utrecht, University of Birmingham, University of Cambridge, Uppsala Clinical Research Center, Uppsala University, Vifor Pharma

Read more about the BigData@Heart project here.